Lilly's Foundayo Pill Matched Insulin on Heart Safety in Lancet Trial, but Its Lower Death Rate Needs Caution

Eli Lilly's experimental drug, retatrutide, showed up to 28.3% weight loss in late-stage trials, outperforming Ozempic's typical results. The drug targets three hormone pathways, unlike Ozempic's single pathway. Retatrutide is not yet approved and lacks direct comparison trials. Eli Lilly plans to submit it for U.S. regulatory review in 2027.

Eli Lilly received approval to build a $3 billion pharmaceutical plant in Katwijk, Netherlands, focusing on diabetes and weight-loss medicines. The project, bringing 500 jobs, was approved by the municipal council despite local opposition. Additional permits are needed for production and wastewater discharge. The company cited proximity to airports and the Leiden Bio Science Park as key factors for the location.

Eli Lilly's experimental drug combination, EloraTZP (eloralintide + tirzepatide), showed 23.3% weight loss in a 48-week Phase 2 trial for adults with obesity and type 2 diabetes, per Lilly's Sept. 30 release. The highest-dose group lost 54 pounds, compared to 34 pounds with tirzepatide alone. The combination also reduced A1C levels more. However, up to 27% of participants discontinued due to side effects. Lilly plans Phase 3 trials by 2026.

Eli Lilly (LLY) reported that EloraTZP showed greater weight loss than tirzepatide alone in a 48-week study, but had higher discontinuation rates due to adverse events. Shares fell 0.8% to $1,148.00, trading below GF Value by 26.51%. Lilly plans Phase 3 trials with an optimized dose schedule.

Eli Lilly (LLY) reported Phase 2b and Phase 3 trial results for EloraTZP and retatrutide, showing significant weight loss and A1C reductions in obesity and type 2 diabetes patients. The company plans to advance both candidates to later-stage trials and regulatory submissions. These results could expand Lilly's cardiometabolic portfolio and reinforce its growth narrative in obesity treatments.

Eli Lilly's orforglipron met noninferiority criteria for CV outcomes in a phase 3 trial, showing improvements in glycemia and bodyweight. The drug was approved in the US for weight management and is under review for T2D treatment. The trial compared orforglipron to insulin glargine, with 4.2% of patients on orforglipron experiencing major adverse CV events vs 5.0% on glargine. Orforglipron showed superiority in A1c and body weight reduction but not in MACE-3 outcomes.